Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab

被引：5

作者：

Costa Arpin, Eva ^{[1
]}

Garcia Sobrino, Tania ^{[1
]}

Dominguez Vivero, Clara ^{[1
]}

Amigo Jorrin, Maria del Campo ^{[2
]}

Rodriguez Regal, Ana ^{[2
]}

Prieto Gonzalez, Jose ^{[1
]}

Lema Bouzas, Manuela ^{[1
]}

机构：

[1] Hosp Clin Univ, Dept Neurol, Santiago De Compostela, Spain

[2] Complejo Hosp Pontevedra, Dept Neurol, Pontevedra, Spain

来源：

NEURODEGENERATIVE DISEASE MANAGEMENT | 2016年 / 6卷 / 01期

关键词：

brain atrophy; corpus callosum index; multiple sclerosis; natalizumab;

D O I：

10.2217/nmt.15.53

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Aim: To evaluate the effect of natalizumab on progression of brain atrophy in multiple sclerosis (MS) patients and to search for a clinical or radiological marker of progression of brain atrophy. Patients and methods: We retrospectively recorded demographic and clinical data, as well as the corpus callosum index (CCI) using MRI, in MS patients treated with natalizumab for 1-4 years. Results: In the study population (n = 29), baseline mean CCI was 0.37 +/- 0.04 and final CCI 0.36 +/- 0.04. 17 patients did not develop brain atrophy during follow-up. There was no statistically significant relationship between progression of atrophy and clinical and radiological parameters. Conclusion: Natalizumab may have a neuroprotective effect.

引用

页码：5 / 12

页数：8

共 38 条

[1] Dual destructive and protective roles of adaptive immunity in neurodegenerative disorders [J].

Anderson K.M. ;

Olson K.E. ;

Estes K.A. ;

Flanagan K. ;

Gendelman H.E. ;

Mosley R.L. .

Translational Neurodegeneration, 3 (1)

[2] Voxel-based analysis of grey matter magnetization transfer ratio maps in early relapsing remitting multiple sclerosis [J].

Audoin, B. ;

Davies, G. ;

Rashid, W. ;

Fisniku, L. ;

Thompson, A. J. ;

Miller, D. H. .

MULTIPLE SCLEROSIS JOURNAL, 2007, 13 (04) :483-489

[3] The clinico-radiological paradox in multiple sclerosis revisited [J].

Barkhof, F .

CURRENT OPINION IN NEUROLOGY, 2002, 15 (03) :239-245

[4] Imaging outcomes for neuroprotection and repair in multiple sclerosis trials [J].

Barkhof, Frederik ;

Calabresi, Peter A. ;

Miller, David H. ;

Reingold, Stephen C. .

NATURE REVIEWS NEUROLOGY, 2009, 5 (05) :256-266

[5] The measurement and clinical relevance of brain atrophy in multiple sclerosis [J].

Bermel, RA ;

Bakshi, R .

LANCET NEUROLOGY, 2006, 5 (02) :158-170

[6] Grey matter pathology in clinically early multiple sclerosis: Evidence from magnetic resonance imaging [J].

Chard, Declan ;

Miller, David .

JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 282 (1-2) :5-11

[7] Brain atrophy in clinically early relapsing-remitting multiple sclerosis [J].

Chard, DT ;

Griffin, CM ;

Parker, GJM ;

Kapoor, R ;

Thompson, AJ ;

Miller, DH .

BRAIN, 2002, 125 :327-337

[8] Back to the future for multiple sclerosis therapy: focus on current and emerging disease-modifying therapeutic strategies [J].

Croxford, J. Ludovic ;

Yamamura, Takashi .

IMMUNOTHERAPY, 2009, 1 (03) :403-423

[9] Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis [J].

Evangelou, N ;

Konz, D ;

Esiri, MM ;

Smith, S ;

Palace, J ;

Matthews, PM .

BRAIN, 2000, 123 :1845-1849

[10]

Evangelou N, 2000, ANN NEUROL, V47, P391, DOI 10.1002/1531-8249(200003)47:3<391::AID-ANA20>3.3.CO

← 1 2 3 4 →